A Prospective Study Of Pregnancies Exposed to UCB Antiepileptic Drugs to Determine if There is a Potential Increase in the Risk of Major Birth Defects.

Trial Profile

A Prospective Study Of Pregnancies Exposed to UCB Antiepileptic Drugs to Determine if There is a Potential Increase in the Risk of Major Birth Defects.

Completed
Phase of Trial: Phase IV

Latest Information Update: 15 Sep 2016

At a glance

  • Drugs Levetiracetam (Primary) ; Antiepileptic drugs
  • Indications Epilepsy
  • Focus Adverse reactions
  • Sponsors UCB
  • Most Recent Events

    • 01 Sep 2016 Status changed from active, no longer recruiting to completed.
    • 22 Dec 2015 Planned End Date changed from 1 Aug 2016 to 1 Mar 2016 as per ClinicalTrials.gov record.
    • 22 Dec 2015 Planned primary completion date changed from 1 Aug 2016 to 1 Mar 2016 as per ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top